In short
Raludotatug Deruxtecan (R-DXd) is being investigated in a groundbreaking clinical trial for patients with advanced or metastatic solid tumors. This study, known as REJOICE-PanTumor01, aims to evaluate the effectiveness and safety of R-DXd in various cancer types, including gynecological and genitourinary cancers. The trial focuses on tumors with different levels of cadherin-6 (CDH6) expression, a protein that may play a role in cancer progression.
At a glance
- Study Name
- REJOICE-PanTumor01
- Drug
- Raludotatug Deruxtecan (R-DXd)
- Cancer Types
- Advanced/metastatic solid tumors, including gynecological and genitourinary cancers
- Administration
- Intravenous, every 3 weeks
- Primary Endpoints
- Objective Response Rate (ORR), Disease Control Rate (DCR), Safety and Tolerability
- Secondary Endpoints
- Progression-free Survival, Duration of Response, Time to Response, Pharmacokinetics
- Study Duration
- Up to 32 months
- Key Feature
- Focus on tumors with various cadherin-6 (CDH6) expression levels
What is Raludotatug Deruxtecan?
Raludotatug Deruxtecan, also known as R-DXd, is an innovative drug being studied for the treatment of advanced or metastatic solid tumors. Advanced tumors are those that have grown and spread within the organ where they started, while metastatic tumors have spread to other parts of the body. This medication is currently undergoing clinical trials to evaluate its effectiveness and safety in treating various types of cancer.
Which Cancers Does Raludotatug Deruxtecan Target?
The clinical trial for Raludotatug Deruxtecan is focusing on several types of solid tumors, particularly those that express a protein called cadherin-6 (CDH6). The specific cancer types being studied include:
- Gynecological cancers:
- Endometrial cancer (cancer of the uterus lining)
- Cervical cancer (cancer of the cervix)
- Non-high-grade serous ovarian cancer (a specific type of ovarian cancer)
- Genitourinary cancers:
- Urothelial cancer (cancer of the bladder lining and urinary system)
- Clear cell renal cell carcinoma (ccRCC) (a type of kidney cancer)
How Does Raludotatug Deruxtecan Work?
While the exact mechanism of action is not fully described in the provided information, Raludotatug Deruxtecan is likely an antibody-drug conjugate (ADC). ADCs are a class of targeted cancer treatments that combine a monoclonal antibody with a potent anti-cancer drug. The antibody part of the medication targets specific proteins on cancer cells, such as CDH6, allowing the drug to be delivered directly to the tumor cells while minimizing damage to healthy cells.
The REJOICE-PanTumor01 Clinical Trial
The clinical trial studying Raludotatug Deruxtecan is called REJOICE-PanTumor01. It is a Phase 2, multicenter, open-label trial designed to evaluate the efficacy and safety of the drug in patients with advanced or metastatic solid tumors. The trial is divided into several cohorts, each focusing on a specific type of cancer:
- Endometrial Cancer Cohort
- Cervical Cancer Cohort
- Non-high-grade Serous Ovarian Cancer Cohort
- Urothelial Cancer Cohort
- Clear Cell Renal Carcinoma (ccRCC) Cohort
How is Raludotatug Deruxtecan Administered?
Raludotatug Deruxtecan is administered intravenously (through a vein) every three weeks (Q3W). This means that patients receive the medication once every 21 days, which is considered one treatment cycle. The exact dosage and duration of treatment will be determined by the study investigators based on the patient's response and tolerability.
How Will the Drug's Effectiveness be Measured?
The trial will use several measures to evaluate the effectiveness of Raludotatug Deruxtecan:
- Objective Response Rate (ORR): This is the primary measure for all cohorts except ccRCC. It represents the proportion of patients whose tumors shrink or disappear after treatment.
- Disease Control Rate (DCR): This is the primary measure for the ccRCC cohort. It includes patients whose tumors shrink, disappear, or remain stable for at least 5 weeks.
- Progression-Free Survival (PFS): This measures how long patients live without their cancer getting worse.
- Duration of Response (DoR): This measures how long the tumor response lasts in patients who respond to the treatment.
- Time to Response (TTR): This measures how quickly patients respond to the treatment.
Safety Monitoring During the Trial
The safety of Raludotatug Deruxtecan is a primary concern in the clinical trial. Researchers will closely monitor patients for any side effects or adverse reactions. They will track:
- Treatment-emergent Adverse Events (TEAEs): Any new or worsening medical issues that occur during treatment.
- Serious Adverse Events (SAEs): Any severe or life-threatening reactions.
- Adverse Events of Special Interest (AESIs): Specific side effects that the researchers are particularly interested in monitoring.
Additional Studies on Raludotatug Deruxtecan
In addition to evaluating the drug's effectiveness and safety, the trial will also conduct other studies:
- Pharmacokinetic studies: These will measure how the drug moves through the body, including its maximum concentration (Cmax) in the blood.
- Anti-Drug Antibody (ADA) studies: These will check if patients develop antibodies against the drug, which could potentially affect its effectiveness or safety.
The REJOICE-PanTumor01 trial represents an important step in the development of Raludotatug Deruxtecan as a potential treatment for various advanced solid tumors. As the trial progresses, more information will become available about the drug's effectiveness and safety profile.